glucuronoxylomannan

an immunosuppressive agent; capsular polysaccharide of Cryptococcus neoformans serotype A containing molar ratios of xylose:mannose:glucuronic acid:O-acetyl of 2:5:1:2; linear (1-3) linked mannan substituted at 2-O-positions by single residues of either xylose or glucuronic acid; structure in first source

Also Known As:

Networked: 67 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kozel, Thomas R: 3 articles (08/2011 - 04/2003)
2.	Casadevall, Arturo: 3 articles (06/2007 - 08/2001)
3.	Levitz, Stuart M: 3 articles (11/2006 - 01/2002)
4.	Boulware, David R: 2 articles (05/2019 - 01/2016)
5.	Kohno, Shigeru: 2 articles (01/2018 - 12/2008)
6.	Dadachova, E: 2 articles (09/2015 - 09/2006)
7.	Yauch, Lauren E: 2 articles (11/2006 - 12/2005)
8.	Casadevall, A: 2 articles (09/2006 - 01/2000)
9.	Bistoni, Francesco: 2 articles (11/2004 - 04/2003)
10.	Vecchiarelli, Anna: 2 articles (11/2004 - 04/2003)

Related Diseases

1.	Cryptococcosis 01/01/2018 - "Dectin-3 Recognizes Glucuronoxylomannan of Cryptococcus neoformans Serotype AD and Cryptococcus gattii Serotype B to Initiate Host Defense Against Cryptococcosis." 12/01/2005 - "Cryptococcus neoformans capsular glucuronoxylomannan (GXM) is shed during cryptococcosis and taken up by macrophages. " 07/01/2001 - "Mechanisms for induction of immunosuppression during experimental cryptococcosis: role of glucuronoxylomannan." 09/01/1995 - "During infection, Cryptococcus neoformans capsular glucuronoxylomannan (GXM) is released into tissues, where it may be associated with a variety of deleterious immunological effects. " 01/15/2001 - "Defined Abs to the Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan (GXM) have been shown to be protective against experimental cryptococcosis. "
2.	Experimental Arthritis 09/01/2004 - "This investigation was planned to assess the therapeutic efficacy of glucuronoxylomannan (GXM) in collagen-induced arthritis (CIA). " 09/01/2004 - "Tolerability and anti-inflammatory effects of glucuronoxylomannan in collagen-induced arthritis."
3.	Infections 09/01/1996 - "Administration of MoAbs to Cryptococcus neoformans capsular glucuronoxylomannan (GXM) can alter the course of infection in mouse models. " 01/01/2023 - "Glucuronoxylomannan intranasal challenge prior to Cryptococcus neoformans pulmonary infection enhances cerebral cryptococcosis in rodents." 10/19/2023 - "In the case of Cryptococcus neoformans, a WHO critical priority fungal pathogen, infection results in antibodies targeting capsular glucuronoxylomannan (GXM). " 01/21/2013 - "The efficiency of the approach to the quantification of the inhibition effect of polysaccharide glucuronoxylomannan (GXM) on the infection efficiency of the tobacco mosaic virus (TMV) was investigated using advanced serological approaches based on label-free surface plasmon resonance technique. " 04/01/2003 - "Disseminated infections by the opportunistic yeast Cryptococcus neoformans are characterized by accumulation in tissues of glucuronoxylomannan (GXM), the major component of the capsular polysaccharide. "
4.	Trichosporonosis 03/01/1999 - "In a study using 11 clinical samples, the specific fragment was detected by the nested PCR in 64% (7 of 11) of sera from patients with histologically diagnosed disseminated trichosporonosis, while glucuronoxylomannan antigen was detected in only 54% (6 of 11) of the samples. " 10/01/2011 - "It is possible that the ability of Trichosporon strains to form biofilms on implanted devices, the presence of glucuronoxylomannan in their cell walls, and the ability to produce proteases and lipases are all factors likely related to the virulence of this genus and therefore may account for the progress of invasive trichosporonosis. " 09/01/2011 - "Disseminated trichosporonosis was determined based on positive blood culture, elevated serum glucuronoxylomannan antigen and beta-D glucan, and the man's lack of clinical progress. " 01/01/1998 - "In trichosporon PCR, Trichosporon 26S rRNA encoding gene was amplified from two strains of Trichosporon species, and detected by the nested PCR in 64 % of serum samples of patients with trichosporonosis, while glucuronoxylomannan antigen was detected in 55 % of samples. "
5.	Cryptococcal Meningitis 05/01/1995 - "Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis." 01/01/2023 - "Glucuronoxylomannan intranasal challenge prior to Cryptococcus neoformans pulmonary infection enhances cerebral cryptococcosis in rodents." 01/01/2016 - "A Glucuronoxylomannan-Associated Immune Signature, Characterized by Monocyte Deactivation and an Increased Interleukin 10 Level, Is a Predictor of Death in Cryptococcal Meningitis." 10/01/1998 - "Does the capsule component of the Cryptococcus neoformans glucuronoxylomannan impair transendothelial migration of leukocytes in patients with cryptococcal meningitis?" 01/01/1998 - "On the basis of the clinical observation that the cerebrospinal fluid (CSF) of patients with cryptococcal meningitis contains high levels of the chemokine interleukin (IL)-8 but few polymorphonuclear leukocytes (PMNL), the production of IL-8 by cultured brain glial cells after stimulation with two serotypes of cryptococcal capsular polysaccharide glucuronoxylomannan (GXM) was studied, followed by an assessment of the effect of GXM on PMNL migration toward IL-8. "

Related Drugs and Biologics

1.	Polysaccharides (Glycans)
2.	Antigens
3.	Antibodies
4.	Biomarkers (Surrogate Marker)
5.	Synthetic Vaccines (Recombinant Vaccines)
6.	Capsules (Microcapsules)
7.	Monoclonal Antibodies
8.	Immunoglobulin G (IgG)
9.	Immunoglobulin M (IgM)
10.	Tetanus Toxoid (Vaccine, Tetanus)

Related Therapies and Procedures

1.	Therapeutics